Sort by
Refine Your Search
-
Scholarship base Merit Based Value CSIRO shall award the student an iPhD Program Scholarship annually (GST exempt), starting at $35,000 (2025 rate), indexed at 3% annually, for a maximum of 4 years. This is
-
Status: Closed Applications open: 3/07/2024 Applications close: 3/10/2024 View printable version [.pdf] About this scholarship Description/Applicant information CSIRO's Industry PhD (iPhD) program
-
transformation in the delivery of Australia’s Opioid Dependence Treatment Program (ODTP) is underway. Reforms commencing in the second half of 2023 will dramatically reduce the costs of treatment. In collaboration
-
of the STAMP RSV Program, supported by the Stan Perron Charitable Foundation. The PhD candidate will play an important role in developing models of RSV transmission and vaccination efficacy to inform
-
Trailblazer builds new research capabilities and drives commercialisation outcomes in the resources technology and critical minerals sector. There will be opportunities to be involved in the Trailblazer Program
-
Status: Open Applications open: 25/11/2024 Applications accepted at any time View printable version [.pdf] About this scholarship Description/Applicant information The CSIRO Industry PhD Program
-
Status: Closed Applications open: 1/07/2024 Applications close: 18/08/2024 View printable version [.pdf] About this scholarship Description/Applicant information Project Overview Peer-based programs
-
to three years of study (with the potential for extension) Scholarship Details Maximum number awarded 1 Eligible courses The successful candidate must enrol into a Doctor of Philosophy (PhD) program
-
Any HDR student wishing to study in biomedical research Eligibility criteria The successful candidate must meet the minimum academic entry requirement for admission into the Doctor of Philosophy program
-
project within an NHMRC-funded program focused on dementia research. Using a systems biology framework, the project will integrate genomic and lifestyle data to identify key molecular pathways and risk